Navigation Links
New published study demonstrates over-the-counter device lowers blood pressure in diabetic patients
Date:3/9/2009

New York, NYMarch 9, 2009InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), today announced a new study published in the peer-reviewed Journal of Human Hypertension. The advance online publication of the study is now available on the journal's website. The study will also be published in the May issue of the journal, Volume 23, Issue 5. It demonstrates use of RESPeRATEthe only medical device cleared by the FDA and CE-approved for the adjunctive treatment of hypertensionfor 15 minutes a day significantly lowered blood pressure in non-insulin dependent diabetics. This study reinforces nine previous studies that validate the efficacy of the device.

The randomized, controlled trial of 66 non-insulin dependent (Type II) diabetic patients with uncontrolled blood pressure was conducted by Moshe H. Schein, MBChB, M.S., Hadassah-Hebrew University Medical Center.

Despite the fact that 82 percent of the study population was already taking antihypertensive medication before the start of the trial, baseline systolic blood pressure levels remained high while diastolic levels were controlled. Study participants using device-guided breathing with RESPeRATE at home for eight weeks experienced a significant reduction in office systolic blood pressure (mean+SE) -10.0+1.8 mm Hg (p< 0.0001), but similar results were not seen in the control group +1.6+2.1 mm Hg (p>0.4). A full 88 percent of patients using RESPeRATE experienced a significant blood pressure reduction, in contrast to only 45 percent of the control group.

"A high percentage of diabetic complications can be attributed to hypertension. However data shows that only 20 percent of diabetic patients reach the recommended target blood pressure," said Dr. Schein, the lead investigator. "It is therefore encouraging that an effective non-drug therapy can help this population improve its blood pressure control. The compliance with treatment in the study was high and in addition the patients reported feeling more relaxed after the device-guided breathing."

Hypertension is a common co-morbidity in patients with diabetes mellitus and is an important factor in the increased risk of coronary heart disease and stroke in diabetics. Lowering blood pressure in the diabetic population is crucially important, yet difficult to achieve. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommends aggressive hypertension treatment for diabetics, including pharmacological and non-pharmacological interventions, in order to reduce blood pressure below 130/80 mm Hg. Despite this aggressive approach, only 44.3 percent achieve blood pressure goals below 140/90 mm Hg and only 20.4 percent reach the recommended target of below 130/80 mm Hg.

"This new study provides a clear demonstration of the non-drug benefits of RESPeRATE among the high-risk diabetes population," said Erez Gavish, president and CEO of InterCure. "Diabetics facing a daily regimen of monitoring, insulin injections and prescription medication for secondary conditions have long supported the truly natural hypertension treatment RESPeRATE provides. Diabetic nurse educators and clinicians across the country now have even more reason to discuss RESPeRATE as a viable option among this hard-to-control, high-risk patient population."


'/>"/>

Contact: Lisa Mokaba
intercure@schwartz-pr.com
781-684-0770
Schwartz Communications
Source:Eurekalert

Related medicine news :

1. Published Data Confirms First 3D Ultrasound for Breast Cancer Treatment Planning Helps Radiation Oncologists Better Define Treatment Region
2. Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology
3. Video: The MDS Foundation Says Published Data Confirms VIDAZA(R) Significantly Extends Survival in Patients with the Malignant Condition MDS
4. Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology
5. Major study on DiagnoCures GCC biomarker published in Jama
6. Newly Published Menopause Study: Bioidentical and FDA-Approved Divigel(R) (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated With Menopause
7. Complete Genomes of All Known Human Rhinoviruses are Published
8. Published Study Shows Brain Exercises Improve Memory and Attention - And People Notice
9. New guidelines for prescribing opioid pain drugs published
10. New Guidelines for Prescribing Opioid Pain Drugs Published
11. Emergency Treatment Strategies, Better Communication Among Health Care Workers Reduce Heart Attack Patient Deaths by 19 Percent, Says AHJ Published Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and ... has selected 21 leaders from government, business and civil society in 11 countries across ... U.S. this fall, engaging in a transformative exchange of knowledge and ideas with the ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance ... With the Federal Emergency Management Agency’s (FEMA) recent update of flood zones, more ... 2012, the Biggert-Waters Act was enacted to reflect the actual risk in flood ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Katyl Agency, ... to families and business owners in and around Lackawanna County, is joining Meals ... in the area. , Meals on Wheels of NEPA provides hand-delivered and nutritious ...
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, a locally ... business owners in North Central West Virginia, is embarking on a cooperative charity ... residents in the region. , The Stepping Stones organization offers a series of ...
(Date:6/22/2017)... ... June 22, 2017 , ... Plastic Surgery Associates is proud to report ... 2017. Each year, research and information firm, Castle Connolly, releases their list of the ... this marks the 3rd time that Dr. Canales has been recognized by ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... , June 8, 2017  Less than a ... hit more than 200,000 companies, including hospital networks, in ... heralded as one of the largest online extortion attempts ... the healthcare market, it is imperative that providers understand ... their data from this — and many other very ...
(Date:6/7/2017)... 6, 2017  Diplomat Specialty Infusion Group, a brand of Diplomat ... its Iowa location. The ... now features an ISO 7 cleanroom—the standard needed to compound intravenous ... low level of pollutants. "Our ... and better serve our Iowa patients," said ...
(Date:6/1/2017)... BELL, Pa. , June 1, 2017 ... (PRN) and Veterinarian Recommended Solutions (VRS), and KD Pharma ... investment in Nutriceutical Holdings by KD Pharma Group. KD ... Holdings with the option to acquire the entire company. ... partner in KD. They are committed to growing the ...
Breaking Medicine Technology: